Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor of MediTouch’s Groundbreaking BalanceTutor™ Rehabilitation System
Rhea-AI Summary
Ekso Bionics (Nasdaq: EKSO) announced an exclusive U.S. distribution agreement with MediTouch to act as the authorized sales agent and distributor for the BalanceTutor™ rehabilitation system in the United States, dated December 4, 2025.
The BalanceTutor uses a patented 4D perturbation treadmill with multiple force and movement sensors to simulate slips, trips, and stumbles while supporting patient weight via an overhead frame to promote safe reactive balance training in inpatient and outpatient rehabilitation settings.
Ekso said the product is complementary to its enterprise health exoskeleton offerings and will be marketed through its existing customer call points to increase awareness and adoption across U.S. physical rehabilitation facilities.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, EKSO declined 5.66%, reflecting a notable negative market reaction. Argus tracked a peak move of +22.0% during that session. Argus tracked a trough of -33.1% from its starting point during tracking. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $917K from the company's valuation, bringing the market cap to $15M at that time. Trading volume was exceptionally heavy at 130.0x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: one notable decliner at -27.18% and others between about -4% and +0.6%, while EKSO was roughly flat at +0.41%, pointing to stock-specific rather than sector-driven dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 04 | Product partnership | Positive | -5.7% | Exclusive U.S. distribution deal for MediTouch BalanceTutor rehabilitation system. |
| Oct 29 | Equity offering | Negative | +9.2% | Registered direct common stock offering raising about $3.7M gross proceeds. |
| Oct 28 | Earnings update | Neutral | -2.2% | Q3 2025 results with modest revenue growth, margin improvement and lower net loss. |
| Jul 28 | Earnings update | Negative | -27.4% | Q2 2025 results showing revenue decline, higher net loss and margin compression. |
| Jul 21 | Earnings preview | Neutral | -2.5% | Announcement of upcoming Q2 2025 results release and conference call details. |
News and financing events have often produced sharp but inconsistent moves, with both positive and negative reactions regardless of the underlying headline tone.
Over the last six months, EKSO has mixed operational and financing milestones. Q2 and Q3 2025 earnings showed revenue volatility and changing margins, with notable negative reactions of -27.37% and -2.24%. A $3.7M registered direct offering on Oct 29, 2025 drew a positive +9.15% move. The current exclusive U.S. BalanceTutor distribution agreement on Dec 4, 2025 coincided with a -5.66% reaction, underscoring a history of choppy trading around both strategic and financial updates.
Market Pulse Summary
The stock moved -5.7% in the session following this news. A negative reaction despite an accretive-looking distribution deal would fit EKSO’s tendency toward volatile responses, including prior moves of -27.37% on weak earnings and -5.66% on this same headline historically. Investors have also recently digested a $3.7M equity offering and executive equity awards, so balance-sheet and governance factors could have amplified downside pressure following otherwise constructive commercial news.
Key Terms
exoskeleton technical
AI-generated analysis. Not financial advice.
SAN RAFAEL, Calif. and TNUVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an agreement with Israel-based MediTouch Inc. (“MediTouch”) to become the exclusive authorized sales agent and distributor of MediTouch’s BalanceTutor™ rehabilitation system in the United States.
The BalanceTutor is the only known rehabilitation system that employs an advanced 4D perturbation patented treadmill and multiple force and movement sensors which allow patients impacted by impaired balance to react to unanticipated disturbances while walking. The BalanceTutor 4D treadmill can move forward, backward, and side-to-side while a patient is standing still or walking to elicit a slip, trip, or stumble. Patient weight is supported by an overhead frame that is designed to promote safe responses to disturbances of balance without the patient risk of experiencing a fall. The BalanceTutor’s proprietary 4D perturbations mimic realistic balance challenges that require a reactive response while maintaining patient and physical therapist safety.
“We are excited to add MediTouch’s BalanceTutor rehabilitation system to our leading technology offerings, expanding our reach in patient care,” commented Ekso Bionics’ Chief Executive Officer, Scott Davis. “We believe the BalanceTutor is synergistic with our current go-to-market strategy by leveraging a common customer call point with a technology that is complementary to our current enterprise health exoskeleton solutions. We look forward to working with MediTouch to help ensure that the groundbreaking BalanceTutor gains awareness, acceptance and adoption by inpatient and outpatient physical rehabilitation facilities across the country.”
“We are thrilled to partner with Ekso Bionics to grow the presence of the BalanceTutor across the U.S.,” said Moshe Druker, VP of Global Business Development at MediTouch. “This collaboration marks an important milestone for MediTouch, enabling us to expand access to our innovative rehabilitation technology and help more individuals regain balance, confidence, and independence.”
About Ekso Bionics
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO." For more information, visit: www.eksobionics.com.
About MediTouch
MediTouch is dedicated to developing and delivering innovative physical rehabilitation solutions for medical centers, outpatient clinics, and home healthcare settings. Our technologies empower clinicians and patients with advanced tools that support effective, engaging, and measurable rehabilitation.
For more information, visit: www.meditouch.co.il.
Forward-Looking Statements
Any statement contained in this press release that does not describe historical facts may constitute a forward-looking statement. Forward-looking statements may include, without limitation, statements regarding the ability of the Company to distribute the BalanceTutor rehabilitation system in the United States, the potential impacts of the Company’s devices to patients using the devices, and the Company’s ability to bolster demand for its products and execute on its long-term growth strategy. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund and grow the Company's operations and to develop or enhance the Company’s technology, the Company’s failure to successfully incorporate the BalanceTutor into its sales strategy on a timely basis or at all, or risks related to product liability, recall and warranty claims. These and other factors are identified and described in more detail in the Company’s filings with the U.S. Securities and Exchange Commission. To learn more about Ekso Bionics please visit the Company’s website at www.eksobionics.com or follow @EksoBionics on X. The Company does not undertake to update these forward-looking statements, except as required by law.
Contact:
Ekso Bionics
Stephen Kilmer
Investor Relations
(646) 274-3580
skilmer@eksobionics.com
FAQ
What did Ekso Bionics (EKSO) announce on December 4, 2025 regarding MediTouch?
What is the BalanceTutor system that EKSO will distribute in the U.S.?
How will the EKSO and MediTouch deal affect hospital and clinic access to BalanceTutor in the U.S.?
Does the announcement state any financial terms or revenue guidance for EKSO (Nasdaq: EKSO)?
What safety features does the BalanceTutor include as described in the EKSO announcement?
Will Ekso market BalanceTutor alongside its existing exoskeleton products?
